Screener
PTC Therapeutics PTCT Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $357.81M+69.6% | $360.52M+102% | $272.55M-76.8% | $164.68M-22.7% | $211.01M+7.2% | ||
| $105.35M+5.2% | $99.15M-12.2% | $100.87M-7.4% | $133.13M+6.7% | $100.16M-37.9% | ||
| $80.08M-4.7% | $80.63M-5.4% | $86.18M+6.5% | $96.87M+14.4% | $84.05M+14.4% | ||
| $332.69M+60.0% | $211.54M-1.1% | $227.59M+10.6% | $236.03M-37.2% | $207.99M-17.2% | ||
| $25.11M+733% | $148.98M+526% | $44.96M-95.4% | $0+100% | $3.02M+106% | ||
| 7%+5.6pp | 41.3%+60.9pp | 16.5%-66.0pp | 0%+76.2pp | 1.4%+29.1pp | ||
| -$45.87M-40.7% | -$48.48M-59.7% | -$49.03M-43.8% | -$55.19M-34.4% | -$32.59M+21.7% | ||
| -$1.07M-117% | -$2.95M+48.6% | $1.61M+126% | -$12.55M-242% | $6.5M+447% | ||
| -$41.09M-78.1% | $97.55M+237% | -$2.46M-100% | —— | -$23.07M+76.5% | ||
| $10.61M+127% | $14.05M+326% | $347K-99.5% | —— | -$38.97M-550% | ||
| -$51.69M-425% | $83.5M+229% | -$2.81M-100% | —— | $15.9M+115% | ||
| -14.4%-22.0pp | 23.2%+59.4pp | -1%-74.7pp | —— | 7.5%+61.7pp | ||
| -$0.62-410% | $0.92+211% | -$0.03-100% | —— | $0.20+114% | ||
| $41.93M+197% | $164.85M+702% | $60.37M-93.8% | $12.9M+108% | $14.13M+129% | ||
| 11.7%+5.0pp | 45.7%+61.0pp | 22.2%-61.0pp | 7.8%+80.8pp | 6.7%+31.1pp | ||
| $25.11M+733% | $148.98M+526% | $44.96M-95.4% | $0+100% | $3.02M+106% |
FAQ
- What is PTC Therapeutics's revenue?
- PTC Therapeutics (PTCT) generated $1.2B in revenue over the trailing twelve months, down 35.0% year over year.
- What are PTC Therapeutics's profit margins?
- Gross margin is 96.0% and operating margin is 19.0%, with a 42.3% net margin.
- Where does PTC Therapeutics's income statement data come from?
- Every line is extracted from PTC Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
